Clik here to view.
Biopharmaceuticals: Pricing For Clinical Value And In-Market Risk
Prescription drug pricing has become a very hot topic in the last year. The public policy debate began in earnest with the market launch of Gilead’s Hepatitis C cure, Sovaldi, in 2014, sparking a...
View ArticleClik here to view.
The Payment Reform Landscape: Specialty Pharmacy — Can Payment Reform Offer...
The number of specialty pharmaceuticals available has increased from 10 to more than 900 over the last 20 years. This is good news for the patients who sorely need these drugs to improve, or even...
View ArticleClik here to view.
The Impact Of New Hepatitis C Drugs On National Health Spending
Those who follow Altarum Institute’s monthly health sector briefs and trend reports are well aware that the five-year run of record low growth rates in national health spending (from 2009 through 2013)...
View ArticleClik here to view.
2014 National Health Spending: The Great Moderation Likely Is Not Over
Two weeks ago, the Office of the Actuary at the Centers for Medicare and Medicaid Services (CMS) released their 2014 US health spending estimate showing the highest national health spending growth rate...
View ArticleClik here to view.
Six Big Trends To Watch In Health Care For 2016
With the upcoming Presidential election, health care is once again keeping us up at night. How much of the current debate is hyperbolic rhetoric? What policy changes are realistic in an election year?...
View ArticleClik here to view.
Is High Prescription Drug Spending Becoming Our New Normal?
Lately it seems as if specialty drugs are everywhere. While it used to be that only a small number of patients were treated using these expensive drugs, manufacturers are increasingly developing...
View ArticleClik here to view.
‘Value Creation’ And ‘Value Shifting’ In Health Care
Corporate executives, the management consultants who advise them, and the financial industry executives who help corporations finance their capital investments tend to believe that whenever their joint...
View ArticleClik here to view.
Making Hepatitis C A Rare Disease In The United States
New breakthrough medicines for Hepatitis C present an important choice about setting goals and taking systemic action to achieve public health advances in the United States. Despite appearing to offer...
View ArticleClik here to view.
Government Appropriation Of Breakthrough Drug Patent Rights Would Deter...
In the May 2016 issue of Health Affairs, Amy Kapczynski and Aaron Kesselheim propose that the federal government invoke its patent use authority under Section 1498 to lower drug prices and increase...
View ArticleClik here to view.
The Cost Of A Cure: Revisiting Medicare Part D And Hepatitis C Drugs
Two years ago, soon after the Food & Drug Administration (FDA) approved the first breakthrough treatment for hepatitis C, we wrote about the potential cost of a cure to Medicare Part D and its...
View Article